001     300163
005     20250518020537.0
024 7 _ |a pmid:40140136
|2 pmid
024 7 _ |a 0960-8923
|2 ISSN
024 7 _ |a 1708-0428
|2 ISSN
024 7 _ |a DOI:10.1007/s11695-025-07829-1
|2 doi
024 7 _ |a DOI:10.1007/s11695-025-07829-1
|2 doi
024 7 _ |a altmetric:175684416
|2 altmetric
037 _ _ |a DKFZ-2025-00649
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Betzler, Johanna
|0 P:(DE-He78)79e2e48100b40ab9f33fb2cb119d6f07
|b 0
|e First author
|u dkfz
245 _ _ |a Antireflux Surgery in Patients with Moderate Obesity - Fundoplication or Roux-en-Y Gastric Bypass?
260 _ _ |a New York, NY
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1747057027_33
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B440# / 2025 May;35(5):1750-1760
520 _ _ |a Gastroesophageal reflux disease (GERD), often associated with obesity, impairs quality of life and can lead to complications. This study compared Fundoplication and Roux-en-Y Gastric Bypass (RYGB) in patients with WHO (World Health Organization) class I and II obesity and refractory GERD.A single-center, retrospective study analyzed 93 patients (55 Fundoplication, 38 RYGB) with BMI < 40 kg/m2 who underwent surgery between January 2018 and September 2021. Preoperative characteristics, surgical outcomes, and postoperative results after three months and after one year were analyzed. Quality of life was assessed using Bariatric Quality of Life (BQL) and Quality of Life in Reflux and Dispepsia (QOLRAD) questionnaires. Propensity-score matching (PSM) was performed using the parameters age, BMI and gender.Patients who underwent RYGB had higher preoperative BMI (35.9 vs. 27.5 kg/m2, p < 0.0001) and more metabolic comorbidities. Patients who underwent Fundoplication experienced longer anesthesia (192.5 vs. 112 min, p < 0.0001), operation times (134 vs. 79 min, p < 0.0001), and hospital stays (4 vs. 3 days, p = 0.0003). Complication rates in general (p = 0.0154, after three months) and dysphagia rates in particular (p = 0.0036, after three months and p = 0.0147, after one year) were higher in the Fundoplication group. Preoperatively, patients undergoing RYGB reported poorer quality of life in BQL questionnaires (p = 0.0008). PSM showed less reflux regression in the Fundoplication group after three months (p = 0.0223).Despite higher preoperative BMI and comorbidities, patients undergoing RYGB had shorter operative times and hospital stays. The results suggest RYGB may be preferable for patients with refractory GERD and class I and II obesity, but further research on long-term outcomes is needed.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Antireflux surgery
|2 Other
650 _ 7 |a Fundoplication
|2 Other
650 _ 7 |a GERD
|2 Other
650 _ 7 |a Moderate obesity
|2 Other
650 _ 7 |a RYGB
|2 Other
700 1 _ |a Wiegand, Nina
|b 1
700 1 _ |a Kantorez, Alexandra
|b 2
700 1 _ |a Finze, Alida
|b 3
700 1 _ |a Schölch, Sebastian
|0 P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e
|b 4
|u dkfz
700 1 _ |a Reißfelder, Christoph
|b 5
700 1 _ |a Otto, Mirko
|b 6
700 1 _ |a Blank, Susanne
|b 7
773 _ _ |a DOI:10.1007/s11695-025-07829-1
|0 PERI:(DE-600)2087903-9
|n 5
|p 1750-1760
|t Obesity surgery
|v 35
|y 2025
|x 0960-8923
909 C O |p VDB
|o oai:inrepo02.dkfz.de:300163
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)79e2e48100b40ab9f33fb2cb119d6f07
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a9d57fe3333789705a9ceb9ca904e83e
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b OBES SURG : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
920 1 _ |0 I:(DE-He78)B440-20160331
|k B440
|l NWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle
|x 0
920 1 _ |0 I:(DE-He78)A430-20160331
|k A430
|l NWG-KKE Translationale Chirurgische Onkologie
|x 1
920 0 _ |0 I:(DE-He78)B440-20160331
|k B440
|l NWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B440-20160331
980 _ _ |a I:(DE-He78)A430-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21